High time for low-dose prospective clinical trials

Cancer

Volumn 98, Issue 8, 2003, Pages 1559-1561

  DiPaola, Robert S ^a   Durivage, Henry J ^a   Kamen, Barton A ^a  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; PACLITAXEL; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; VINCRISTINE;

ANTIGEN DETECTION; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CLINICAL RESEARCH; CLINICAL TRIAL; DISEASE SEVERITY; DOSE RESPONSE; DRUG DELIVERY SYSTEM; EVALUATION; HUMAN; LOW DRUG DOSE; MALE; MEDICAL RECORD; METRONOMIC THERAPY; OUTCOMES RESEARCH; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; RETROSPECTIVE STUDY; REVIEW; SALVAGE THERAPY; SIDE EFFECT; TREATMENT FAILURE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS; CYCLOPHOSPHAMIDE; DEXAMETHASONE; HUMANS; MALE; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS;

EID: 0141993045     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11709     Document Type: Review

References (25)

1. Glode LM, Barqawi A, Crighton F, Crawford ED, Kerbel R. Metronomic therapy with cyclophosphamide and dexamethasone for prostate carcinoma. Cancer. 2003;98:1643-1648.
2. DiPaola RS, Zhang H, Lambert G, et al. Clinical and biological activity of an estrogenic herbal combination (PC-SPES) in prostate cancer. N Engl J Med. 1998;339:785-791.
3. Kantoff PW, Halabi S, Conaway M, et al. Hydrocortisone with and without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol. 1999;17:2506-2513.
4. Tannock IF, Osoba D, Stockler MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol. 1996;14:1756-1764.
5. Loprinzi C, Rajkumar SV. Why not start with thalidomide? J Clin Oncol. 2003;21:2211-2214.
6. Garber K. Could less be more? Low-dose chemotherapy goes on trial. J Natl Cancer Inst. 2002;94:82-84.
7. Kamen BA, Rubin E, Glatstein E, Aisner J. High time chemotherapy or high time for low dose. J Clin Oncol. 2000;18: 2935-2937.
8. Hanahan D, Bergers G, Bergsland E. Less is more, regularly: metronomic dosing of cytotoxic drugs can target angiogenesis in mice. J Clin Invest. 2000;105:1045-1047.
9. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420:860-867.
10. Colleoni M, Rocca A, Sandri MT, et al. Low dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. Ann Oncol. 2002;13:73-80.
11. Citron ML, Berry DA, Cirrincione C, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as post-operative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol. 2003;21: 1431-1439.
12. Browder T, Butterfield CE, Kräling BM, et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res. 2000;60:1878-1886.
13. Klement G, Baruchel S, Rak J, et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest. 2000;105:R15-R24.
14. Wang J, Lou P, Lesniewski R, Henkin J. Paclitaxel at ultra low concentrations inhibits angiogenesis without effecting cellular microtubule assembly. Anticancer Drugs. 2003;14:13-19.
15. Vacca A, Iurlaro M, Ribatti D, et al. Antiangiogenesis is produced by non-toxic doses of vinblastine. Blood. 1999;94: 4143-4155.
16. Weitman SD, Glatstein E, Kamen BA. Back to the basics: the importance of concentration x time in oncology. J Clin Oncol 1993;11:820-821.
17. Petrylak DP, Macarthur RB, O'Connor J, et al. Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer. J Clin Oncol. 1999;17:958-967.
18. Roth BJ, Yeap BY, Wilding G, Kasimis B, McLeod D, Loehrer PJ. Taxol in advanced, hormone refractory carcinoma of the prostate. A Phase II trial of the Eastern Cooperative Oncology Group. Cancer. 1993;72:2457-2460.
19. Trivedi C, Redman B, Flaherty LE, et al. Weekly 1-hour infusion of paclitaxel. Clinical feasibility and efficacy in patients with hormone-refractory prostate carcinoma. Cancer. 2000;89:431-436.
20. DiPaola RS, Rafi M, Vyas V, et al. Phase I clinical and pharmacologic study of 13-cis retinoic acid, alpha interferon and paclitaxel in patients with prostate cancer and other advanced malignancies. J Clin Oncol. 1999;17:2213-2218.
21. Thalasila A, Poplin E, Shih J, et al. A phase I trial of weekly paclitaxel, 13- cis-retinoic acid, and interferon alpha in patients with prostate cancer and other advanced malignancies. Cancer Chemother Pharmacol. 2003;52:119-124.
22. Hussain M, Petrylak D, Fisher E, Tangen C, Crawford D. Docetaxel (Taxotere) and estramustine versus mitoxantrone and prednisone for hormone-refractory prostate cancer: scientific basis and design of Southwest Oncology Group Study 9916. Semin Oncol. 1999;26(Suppl 17):55-60.
23. Hanks GE. The dangers of ad hoc protocols. J Clin Oncol. 1984;2:1177-1178.
24. George SL. Reducing patient eligibility criteria in cancer clinical trials. J Clin Oncol. 1996;14:1364-1370.
25. Joseph RR. Viewpoints and concerns of a clinical trial participant. Cancer. 1994;74:2692-2693.